Discover
Fractals: Life Science Conversations
Fractals: Life Science Conversations
Author: The Bracken Group
Subscribed: 3Played: 7Subscribe
Share
Description
Insightful, informative, and warmly good-humored, Fractals features life sciences leaders sharing wisdom, career highs and lows, and compelling stories from the intersections of clinical development, health care, and technology. Presented by The Bracken Group.
40 Episodes
Reverse
A roadmap can set the direction. What actually gets a clinical trial moving?In this episode of Fractals: Life Science Conversations, Rob King of Pivotal CRO joins Colin Miller to unpack Operation TrialBlazer—and ask whether its ambitions address the practical barriers slowing U.S. clinical research.With more than 30 years of experience across CROs, biotech, government, and academia, Rob brings a global perspective to the discussion:Why sponsors look beyond the U.S. for early-phase trialsHow site contracting can undermine efforts to accelerate developmentWhy eligibility criteria deserve scrutiny before a protocol is finalizedWhere CROs need to challenge sponsors and contribute earlierHow sponsors can distinguish actionable changes from proposals still taking shapeA candid conversation about what it takes to turn policy ambitions into progress for sponsors, sites, and patients.
Life sciences doesn’t have a data problem. It has a making-sense-of-the-data problem.In this episode of Fractals: Life Science Conversations, Jo Halliday, CEO and Founder of Talking Medicines, joins host Colin Miller to explore how AI, natural language processing, and real-world signals can help life science organizations better understand what patients and healthcare professionals are actually saying—and turn those insights into better decisions.From the episode:Why unstructured healthcare conversations can reveal insights traditional datasets missHow Talking Medicines evolved from collecting first-party patient data to analyzing signals across multiple sourcesWhat rapidly changing GLP-1 conversations tell us about increasingly informed and empowered patientsHow message resonance and behavioral trends can help pharma determine whether its communications are actually moving the needleWhy the future of AI in life sciences will be less about the technology itself—and more about the questions it can help answer
Imaging has traditionally been used to document what (already) happened. What if it could help determine what happens next?
On the newest episode of Fractals, Colin Miller is joined by Fidēs Imaging CEO Roughan Sheedy and Head of Women’s Health Beth Fisher to discuss how advanced imaging can support earlier, sharper development decisions.
They explore:
Why early-phase programs need more than standardized endpoints
How imaging biology in motion can uncover previously invisible phenomena
Where dynamic imaging may add value across GI disease, women’s health, fibrosis, inflammation, and solid tumors
What it will take for emerging imaging endpoints to earn regulatory credibility
What happens when human health, animal health, and entrepreneurial drug development intersect?
In this episode of Fractals: Life Science Conversations, Bracken CEO Colin Miller is joined by Senior Partners Graham Lumsden, BVM&S, Dip.M., MRCVS, and Jonathan Larkin, PhD, to discuss osteoarthritis innovation, One Medicine, and the collaborative pathways that can move novel therapies forward.
Together, they discuss:
Why osteoarthritis remains a major unmet need in both human and animal health
How disease-modifying approaches could shift treatment beyond pain management
The promise of bispecific antibody development in addressing both pain and cartilage degeneration
How animal health studies can help inform human development programs, and vice versa
Why human expertise, networks, and scientific judgment remain essential in the age of AI
Tune in to Fractals on your preferred podcast platform, and reach out to Bracken to learn how we help life science teams connect strategy, science, and execution across development.
Pharmaceutical manufacturing still struggles with a fundamental challenge: turning complex science into reliable, scalable, real-world processes.
Dr. Michael Choi has spent his career solving exactly that.
As Founder of PCTS and a pioneer in tablet coating simulation, Michael has developed tools that bring clarity to one of the most complex—and often misunderstood—steps in drug production.
In this episode of Fractals: Life Science Conversations, Michael and host Colin Miller discuss:
The hidden variability behind coating uniformity, and why probability sits at the core of the process
How small, overlooked variables (like minor temperature shifts) can drive major manufacturing failures
Why “more advanced” technology doesn’t always mean better outcomes without grounding in fundamentals
The growing gap between sophisticated modelling tools and the teams who need them most
How digital twins, continuous manufacturing, and AI could converge to transform production over the next decade
At its core, this episode is about making science usable: bridging theory and execution to deliver better outcomes across the product lifecycle.
Listen now on your preferred platform—and connect with Bracken to learn how we help translate complex science into actionable strategy.



